Home Alzheimer’s Disease Low-Dose Erlotinib Shows Promise in Elderly, Frail Patients with EGFR+ NSCLC

Low-Dose Erlotinib Shows Promise in Elderly, Frail Patients with EGFR+ NSCLC

A multicenter phase II trial published in JAMA Oncology indicated that low-dose erlotinib (Tarceva) appears to be safe and effective in elderly or frail patients with EGFR mutation-positive non-small cell lung cancer (NSCLC) and could be a valid treatment option. 

However, more research on the dosing strategy of target-based drugs is warranted according to the researchers, especially in frail patients in the real-world setting. 

“With the increased number of elderly and frail patients with cancer, more patients would receive benefit from this value-based treatment to enhance risk-benefit and cost-benefit ratios,” the authors wrote. “In fact, our low-dose erlotinib therapy could substantially reduce the treatment cost.” 

In this single-arm phase II trial, frail patients were enrolled from 21 Japanese institutions after meeting the inclusion critera. Those who were eligible…

Continue Reading to the Source

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Parasite found in undercooked meat linked with risk of rare brain cancer

submitted by /u/Meat_Mithkabob Continue Reading to the Source

Living up to expectations : braincancer

Hey everyone!I wrote a little something about some of the comments you often hear from others and how sometimes you feel like you need...

My Brain Tumor Taught Me To Shift My Perspective on These 5 Things

submitted by /u/andrewjoegeorge Continue Reading to the Source

Recent Comments